Regulatory hurdles regarding the marketing of its prenatal drug, Makena, contributed to KV Pharmaceutical Co.'s continuing losses for the third fiscal quarter.
The Bridgeton-based drug maker reported a net loss of $37.8 million, or 63 cents a share, in the quarter ended Dec. 31, compared to a loss of $47.8 million, or 96 cents a share, a year ago.
Net revenues rose to $5.1 million from $3.5 million. Those revenues were outweighed by the company's operating and other expenses, which totaled $41 million in the third fiscal quarter.
"There is substantial doubt about the company's ability to continue as a going concern," KV said in a filing with the Securities and Exchange Commission.